• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

GBT Supports Sickle Cell Patients During COVID-19 Pandemic


Global Blood Therapeutics (GBT) is taking proactive measures to support public health efforts and sickle cell disease (SCD) patients during the global COVID-19 pandemic.

To help stem the spread of the coronavirus, the company is backing public health strategies, including social distancing. Specifically, GBT is temporarily prohibiting all field team in-person interactions, including visits to physicians, clinics, hospitals and payers.

GBT also seeks to assure SCD patients that GBT Source, the company’s support program for those prescribed Oxbryta, remains available to help with new enrollments and reimbursement, as well as financial, co-pay, treatment adherence, and refill support.

 

https://www.onescdvoice.com/wp-content/uploads/2020/05/GBT-Supports-Sickle-Cell-Patients.jpg